Table 3. The volume and mass inhibition of hepatoma in nude mice after different treatments.

Group	Tumor volume inhibition rate (%, mean ± s, n = 5)	Tumor mass inhibition rate (%, mean ± s, n = 5)
Adriamycin group	76.66 ± 5.362,4,5	77.23 ± 3.84b,e
nuclide-alone group	35.73 ± 11.601,3,4,5	37.50 ± 11.38a,c,d,e
MFH-alone group	78.11 ± 6.822,4,5	76.67 ± 7.41b,e
nuclide-gene group	68.07 ± 6.141,2,3,5	75.58 ± 4.43b,e
nuclide-gene-MFH group	96.38 ± 1.561,2,3,4	94.17 ± 3.12a,b,c,d

Tumor volume inhibition rate: ¹p < 0.05 versus adriamycin group; ²p < 0.001 versus nuclide-alone group; ³p < 0.001 versus MFH-alone group; ⁴p < 0.05 versus nuclide-gene group; ⁵p < 0.001 versus nuclide-gene-MFH group. Tumor mass inhibition rate: ^a p < 0.05 versus adriamycin control group; ^bp < 0.001 versus nuclide-alone group; ^cp < 0.05 versus MFH-alone group; ^dp < 0.05 versus nuclide-gene group; ^ep < 0.001 versus nuclide-gene-MFH group. These measurements were obtained after treatment for 6 weeks.